2L
GYRE icon

22NW LP’s Gyre Therapeutics GYRE Stock Holding History

22NW LP’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-190,566
Closed -$5.87M – 27
2021
Q3 		$5.87M Hold
190,566
– – 1.75% 24
2021
Q2 		$6.19M Buy
190,566
+87,196
+84% +$2.99M 1.66% 25
2021
Q1 		$3.91M Buy
103,370
+395
+0.4% +$18.1K 1.2% 31
2020
Q4 		$4.87M Hold
102,975
– – 1.74% 24
2020
Q3 		$3.32M Buy
102,975
+4,863
+5% +$190K 1.68% 25
2020
Q2 		$4.32M Hold
98,112
– – 2.34% 13
2020
Q1 		$3.22M Hold
98,112
– – 2.5% 11
2019
Q4 		$5.01M Hold
98,112
– – 5.69% 6
2019
Q3 		$3.61M Buy
98,112
+61,454
+168% +$3.31M 4.77% 8
2019
Q2 		$2.03M Buy
36,658
+17,665
+93% +$1.1M 2.19% 19
2019
Q1 		$1.16M Hold
18,993
– – 0.8% 33
2018
Q4 		$1.12M Buy
+18,993
New +$1.4M 0.7% 39

Other funds holding GYRE

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

22NW LP's GYRE Position: Q4 2021 in Review

22NW LP sold out of Gyre Therapeutics (GYRE) in Q4 2021, closing a stake of 190,566 shares — an estimated $5.87M sold.

22NW LP first reported a position in GYRE in Q4 2018 and held it in 12 quarters. The position peaked at $6.19M in Q2 2021. 51 funds tracked by Wall St. Rank hold GYRE as of Q4 2021.

  • 22NW LP reported no remaining Gyre Therapeutics position as of Q4 2021 after selling out during the quarter.
  • 22NW LP sold 190,566 Gyre Therapeutics shares in Q4 2021, an estimated $5.87M.
  • 22NW LP first reported a position in Gyre Therapeutics in Q4 2018 and held it in 12 quarters.
  • 22NW LP's Gyre Therapeutics position peaked at $6.19M in Q2 2021.
  • 51 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q4 2021.

Based on 22NW LP's 13F filing for Q4 2021, filed 14 Feb 2022.